Aarti Drugs Limited — Updates, 29-01-2025: Press Release

Revenue for Aarti Drugs Limited in Q3 FY25 fell by 6% YoY to Rs. 568.5 Cr, with EBITDA declining 13% YoY to Rs. 62.3 Cr. Despite the weaker performance, PAT slightly increased to Rs. 37.1 Cr, reflecting a 1% YoY growth. For the nine-month period, revenue dropped 10% to Rs. 1,724.8 Cr while PAT declined by 15% to Rs. 105.3 Cr. The API segment experienced a revenue contraction of 5.2% YoY, driven by lower market prices. However, the specialty chemicals segment showed resilience with a 7.6% YoY increase. The company is set to acquire a 26.25% equity stake in Pro-Zeal Green Power for green energy needs, and anticipated trial production at the Gujarat facility for specialty chemicals is expected to enhance capacity utilization moving forward. Despite current challenges, management expresses confidence in achieving a double-digit revenue growth target and improving EBITDA margins in FY26, emphasizing a focused long-term strategy to navigate pricing pressures and market dynamics.